Bulk Inquiry
AZD6482
- KIN-193- Optical Purity: Optically pure
- Soluble in DMSO
- MF: C22H24N4O4
- MW: 408.45
Description
AZD6482 is a potent and selective inhibitor of the p110β isoform of PI3K with an IC50 value of 0.69 nM. In addition, AZD6482 can inhibit the growth of tumors driven by p110β or PTEN-loss in vivo.
More Information
| Parent CAS No. | 1173900-33-8 |
|---|---|
| Chemical Name | (R)-2-(1-(7-Methyl-2-morpholino-4-oxo-4H-pyrido[1,2-a]pyrimidin-9-yl)ethylamino)benzoic acid |
| SMILES | C1(C(O)=O)C(N[C@@H](C2=CC(C)=CN3C(=O)C=C(N4CCOCC4)N=C23)C)=CC=CC=1 |&1:6,r| |
| MFCD | N.A. |
| InChi | InChI=1S/C22H24N4O4/c1-14-11-17(15(2)23-18-6-4-3-5-16(18)22(28)29)21-24-19(12-20(27)26(21)13-14)25-7-9-30-10-8-25/h3-6,11-13,15,23H,7-10H2,1-2H3,(H,28,29)/t15-/m1/s1 |
| InChiKey | IRTDIKMSKMREGO-OAHLLOKOSA-N |
| CID | 44137675 |
| Short Description | PI3K p110β inhibitor |
Related Products
| AXON ID | NAME | FROM PRICE |
|---|---|---|
| 1281 | BEZ 235 |
From $55.00 |
| 1282 | BAG 956 |
From $104.50 |
| 1334 | PIK 75 hydrochloride |
From $77.00 |
| 1362 | PIK 90 |
From $93.50 |
| 1366 | LY 294002 |
From $77.00 |
| 1377 | GDC 0941 bismesylate |
From $88.00 |
| 1380 | PI 103 hydrochloride |
From $66.00 |
| 1417 | TGX 221 |
From $77.00 |
| 1424 | AS 252424 |
From $93.50 |
| 1436 | AS 252424 bispotassium salt |
From $104.50 |
| 1520 | NVP-BBD130 |
From $137.50 |
| 1596 | GSK 2126458 |
From $55.00 |
| 1706 | XL PI3K/mTOR inhibitor |
From $132.00 |
| 1719 | D 106669 |
From $93.50 |
| 1782 | GDC 0980 |
From $88.00 |
| 1797 | NVP-BKM120 |
From $99.00 |
| 1807 | PKI 587 |
From $99.00 |
| 1831 | A 66 |
From $104.50 |
| 1855 | PF 04691502 |
From $99.00 |
| 1912 | GSK 2636771 dihydrochloride |
From $115.50 |
| 2029 | NVP-BGT226 |
From $132.00 |
| 2039 | CZC 24832 |
From $104.50 |
| 2168 | IC 87114 |
From $93.50 |
| 2170 | CAL 101 |
From $104.50 |
Other Categories
Are you sure you would like to remove this item from the shopping cart?
This item is a part of the approved quote. Removing it will remove all quote items from the cart.


